

2nd ERRATA to FDA Briefing Document
Cardiovascular and Renal Drugs Advisory Committee Meeting
NDA 216951
October 26, 2022

1. Section 3.1.2. page 15, second paragraph, first line under Figure 1, the text should read:
“subjects received placebo tablets.....”
2. Section 3.1.4.2, page 21, 2nd paragraph last sentence: Replace “n=88” with “n=21”.
3. Section 3.2, page 25, bullet: Replace “darbepoetin alfa” with “active control”
4. Section 3.2.2.2, page 31, Figure 2: for row “other”, under Dapro column, replace “42” with
“43”.